Lancet Oncol: Use CAR T cell Axicabtagene ciloleucel to treat relapsed/refractory indolent non-Hodgkin's lymphoma
Time of Update: 2021-12-26
ZUMA-5 is a single-arm, multi-center phase 2 trial carried out in 17 medical centers in France and the United States, recruiting histologically confirmed relapses or refractory that have been treated twice before 18 years of age or older Patients with indolent non-Hodgkin's lymphoma (follicular lymphoma or marginal zone lymphoma) are treated with leukocyte depletion and pretreatment chemotherapy, and then a single dose of axicabtagene ciloleucel (2x106 CAR T cells/kg) is infused .
A certain let "Klinefelter syndrome" slip away quietly, the latest "China Consensus" guides and regulates diagnosis and treatment
Time of Update: 2021-04-14
Timing of treatment: It is recommended to start T replacement therapy (TRT) at the beginning of puberty, which can improve the quality of life of patients while avoiding serious complications.
Nat Commun: The team at Central South University released early predictions of disease progress in patients with the new crown
Time of Update: 2020-10-10
studies have reported that the incidence of severe COVID-19 among admitted patients is between 15.7 and 26.1%, and these cases are often associated with abnormal chest computer-scanning (CT) results and clinical laboratory data.
A new drug for multiple sclerosis! Novarhua once a month of ofatumab III clinical efficacy beat Sanofi oral drug Aubagio
Time of Update: 2020-08-27
!-- Webeditor:page title"--August 07, 2020 // -- Novartis recently announced that the New England Journal of Medicine (NEJM), an international authoritative medical journal, ) Positive results from two Phase III clinical studies (ASCLEPIOS I, II) on the treatment of multiple sclerosis (RMS) with monoantigenic drug of often oatumumab (OMBI157) have been published online.
Top 10 best selling multiple sclerosis drugs in the next five years
Time of Update: 2016-10-31
Source: Voice of data 2016-10-31 multiple sclerosis (MS) is a disease with complex mechanism, which has the characteristics of autoimmune disease and neurodegenerative disease However, from the perspe